Compound Evidence File
#EC-2026-0109
APAA (alpha-phenylacetoacetamide) CAS 102-01-2
Filed under Raw Materials. The bureau holds 96 laboratory returns for this compound from 34 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
34 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Mar 2026 | 19 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 17 Mar 2026 | 23 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 10.0 | 10.0 | 11 Apr 2026 | 28 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 10.0 | 10.0 | 2 Nov 2025 | 28 Mar 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 6 Feb 2026 | 13 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 26 May 2026 | 26 Jun 2026 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 10.0 | 10.0 | 10.0 | 13 Feb 2025 | 13 Feb 2025 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Mar 2026 | 13 May 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 26 Feb 2026 | 6 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 9.9 | 9 May 2026 | 5 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 18 Jan 2026 | 17 Apr 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 9 Feb 2026 | 1 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 15 Feb 2026 | 5 Apr 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 12 Jan 2026 | 25 Jul 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 9.4 | 9.4 | 9.4 | 25 Apr 2025 | 25 Apr 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 9.0 | 8.0 | 10.0 | 25 May 2026 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.5 | 6.0 | 9.9 | 25 May 2026 | 25 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 8.5 | 7.3 | 9.1 | 24 May 2026 | 24 May 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 8.4 | 8.4 | 8.4 | 21 May 2025 | 21 May 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 8.1 | 7.0 | 8.8 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 7.8 | 7.3 | 8.3 | 24 May 2026 | 24 May 2026 |
| OmegAminoCASE #VI-2026-0014 | X | 1 | 7.8 | 7.8 | 7.8 | 13 Feb 2025 | 13 Feb 2025 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 7.5 | 7.5 | 7.5 | 2 Apr 2025 | 2 Apr 2025 |
| Atomik LabzCASE #VI-2026-0327 | X | 3 | 7.4 | 6.8 | 8.3 | 9 Jun 2025 | 21 May 2026 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 11 | 6.4 | 3.0 | 9.5 | 3 Jun 2025 | 20 May 2026 |
| InjectifyCASE #VI-2026-0387 | X | 1 | 5.7 | 5.7 | 5.7 | 13 Jun 2025 | 13 Jun 2025 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 5.4 | 5.4 | 5.4 | 11 Jun 2025 | 11 Jun 2025 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 5.2 | 5.2 | 5.2 | 2 Jul 2025 | 2 Jul 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 5.0 | 5.0 | 5.0 | 17 Dec 2024 | 17 Dec 2024 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 4.1 | 4.1 | 4.1 | 2 Apr 2025 | 2 Apr 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 4.1 | 4.1 | 4.1 | 7 May 2025 | 7 May 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Apr 2025 | 2 Apr 2025 |
Open any subject to view the batch-level evidence for APAA (alpha-phenylacetoacetamide) CAS 102-01-2 alone.